产品
编 号：F613264
分子式：C42H60N14O16S4
分子量：1145.27
分子式：C42H60N14O16S4
分子量：1145.27
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 332179-76-7
产品详情
生物活性：
RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models.
体内研究：
RGD-4C (9.11 mg/kg; injection; single dose) inhibits the growth of B16F10 mouse melanoma in vivo.Modified RGD-4C fused with the N-terminus of plant-derived single-chain ribosome inactivating protein saporin (SAP) (called RGD-SAP), (diluted in sodium chloride, 0.9%; i.v.; 200 μL; every 5 days, for 3 times) exerts anti-tumor activity in a model of muscle invasive bladder cancer. RGD-SAP in combination with mitomycin C, a chemotherapeutic drug, increases the survival of mice bearing orthotopic bladder cancer with no evidence of systemic toxicity.
体外研究：
RGD-4C (2.5, 5, 10 μg/mL) inhibits BAE cell proliferation by synthetic form modified with endostatin-derived peptides.
RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models.
体内研究：
RGD-4C (9.11 mg/kg; injection; single dose) inhibits the growth of B16F10 mouse melanoma in vivo.Modified RGD-4C fused with the N-terminus of plant-derived single-chain ribosome inactivating protein saporin (SAP) (called RGD-SAP), (diluted in sodium chloride, 0.9%; i.v.; 200 μL; every 5 days, for 3 times) exerts anti-tumor activity in a model of muscle invasive bladder cancer. RGD-SAP in combination with mitomycin C, a chemotherapeutic drug, increases the survival of mice bearing orthotopic bladder cancer with no evidence of systemic toxicity.
体外研究：
RGD-4C (2.5, 5, 10 μg/mL) inhibits BAE cell proliferation by synthetic form modified with endostatin-derived peptides.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备